EMA Withdrawn: Lyxumia (lixisenatide) — Sanofi Winthrop Industrie

View source ↗

Summary

The European Medicines Agency has withdrawn Lyxumia (lixisenatide) from the market; the decision was made on 27 August 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Lyxumia (lixisenatide)

Snippet

Status: Withdrawn. Therapeutic area: Diabetes Mellitus, Type 2. MAH: Sanofi Winthrop Industrie. Decision date: 27/08/2024